New cancer clinical trial: IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Published on: November 29, 2018 at 12:00PM
Conditions:   Metastatic Cancer;   Recurrent Cancer;   Solid Tumor;   Renal Cell Carcinoma;   Urothelial Carcinoma;   NSCLC;   Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: IRX 2;   Drug: Nivolumab
Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting
https://ift.tt/2PaCspI